{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:13:32Z","timestamp":1788516812193,"version":"build-2803163510"},"reference-count":61,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.2217\/17460913.4.1.13","type":"journal-article","created":{"date-parts":[[2009,2,11]],"date-time":"2009-02-11T12:57:29Z","timestamp":1234357049000},"page":"13-24","source":"Crossref","is-referenced-by-count":14,"title":["Prulifloxacin: Clinical Studies of A Broad-Spectrum Quinolone Agent"],"prefix":"10.1080","volume":"4","author":[{"given":"Gianluca","family":"Giannarini","sequence":"first","affiliation":[{"name":"Department of Urology,University of Pisa,\r          Pisa, Italy Tel.: ; Fax: ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit,Azienda Ospedaliero-Universitaria Pisana,\r          Pisa, Italy Tel.: ; Fax: ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Selli","sequence":"additional","affiliation":[{"name":"Department of Urology,University of Pisa,\r          Pisa, Italy Tel.: ; Fax: ;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2009,2,11]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.1086\/428051"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/511159"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.18.3117"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm357"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/1534734606291676"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464190-00005"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2005.09.009"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.4.1.27"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/copd.2007.2.1.27"},{"key":"e_1_3_2_3_10_1","first-page":"355","article-title":"Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent.","volume":"26","author":"Tougou K","year":"1998","unstructured":"Tougou K , NakamuraA, WatanabeS, OkuyamaY, MorinoA: Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent.Drug Metab. Dispos.26 , 355\u2013359 (1998).","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.4.793"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958002-00002"},{"key":"e_1_3_2_3_13_1","first-page":"276","article-title":"Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration.","volume":"47","author":"Okuyama Y","year":"1997","unstructured":"Okuyama Y , MomotaK, MorinoA: Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration.Arzneimittelforschung47 , 276\u2013284 (1997).","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_2_3_14_1","first-page":"285","article-title":"Pharmacokinetics of prulifloxacin. 2nd communication: pharmacokinetics and effect on hepatic drug-metabolizing enzyme activities after repeated administration and transfer into fetus and milk after a single administration in rats.","volume":"47","author":"Okuyama Y","year":"1997","unstructured":"Okuyama Y , MomotaK, MorinoA: Pharmacokinetics of prulifloxacin. 2nd communication: pharmacokinetics and effect on hepatic drug-metabolizing enzyme activities after repeated administration and transfer into fetus and milk after a single administration in rats.Arzneimittelforschung47 , 285\u2013292 (1997).","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_2_3_15_1","first-page":"293","article-title":"Pharmacokinetics of prulifloxacin. 3rd communication: metabolism in rats, dogs and monkeys.","volume":"47","author":"Okuyama Y","year":"1997","unstructured":"Okuyama Y , MorinoA: Pharmacokinetics of prulifloxacin. 3rd communication: metabolism in rats, dogs and monkeys.Arzneimittelforschung47 , 293\u2013298 (1997).","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1994.tb04007.x"},{"key":"e_1_3_2_3_17_1","first-page":"221","article-title":"Influence of milk on absorption of NM 441, a prodrug type of quinolone antibiotic.","volume":"44","author":"Saito A","year":"1996","unstructured":"Saito A , TaraoF: Influence of milk on absorption of NM 441, a prodrug type of quinolone antibiotic.Jpn. J. Chemother.44(Suppl. 1) , 221\u2013228 (1996).","journal-title":"Jpn. J. Chemother."},{"key":"e_1_3_2_3_18_1","first-page":"263","article-title":"Pharmacokinetics and clinical studies on NM441.","volume":"44","author":"Shiba K","year":"1996","unstructured":"Shiba K , YoshidaM, SakaiO, SaitoA: Pharmacokinetics and clinical studies on NM441.Jpn. J. Chemother.44(Suppl. 1) , 263\u2013278 (1996).","journal-title":"Jpn. J. Chemother."},{"key":"e_1_3_2_3_19_1","first-page":"279","article-title":"Pharmacokinetics in concomitant administration with probenecid and clinical study of NM441.","volume":"44","author":"Totsuka K","year":"1996","unstructured":"Totsuka K , KikuchiK, ShimizuK: Pharmacokinetics in concomitant administration with probenecid and clinical study of NM441.Jpn. J. Chemother.44(Suppl. 1) , 279\u2013288 (1996).","journal-title":"Jpn. J. Chemother."},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199816050-00006"},{"key":"e_1_3_2_3_21_1","first-page":"201","article-title":"Pharmacokinetics and tolerability of prulifloxacin after single oral administration.","volume":"53","author":"Picollo R","year":"2003","unstructured":"Picollo R , BrionN, GualanoVet al.: Pharmacokinetics and tolerability of prulifloxacin after single oral administration.Arzneimittelforschung53 , 201\u2013205 (2003).","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200708060-00005"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199500492-00091"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544120-00007"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.3.739"},{"key":"e_1_3_2_3_26_1","first-page":"1","article-title":"Cellular uptake and intraphagocytic activity of the new fluoroquinolone AF 3013 against Klebsiella pneumoniae.","volume":"25","author":"Tullio V","year":"1999","unstructured":"Tullio V , CuffiniAM, BoninoA, Ianni PalarchioA, RossiV, CarloneNA: Cellular uptake and intraphagocytic activity of the new fluoroquinolone AF 3013 against Klebsiella pneumoniae.Drugs Exp. Clin. Res.25 , 1\u201311 (1999).","journal-title":"Drugs Exp. Clin. Res."},{"key":"e_1_3_2_3_27_1","first-page":"791","article-title":"In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Klebsiella pneumoniae, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin.","volume":"55","author":"Shimizu M","year":"2002","unstructured":"Shimizu M , TabataM, HaraT, AraakeM, WatabeH, NishinoT: In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Klebsiella pneumoniae, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin.Jpn. J. Antibiotic.55 , 791\u2013799 (2002).","journal-title":"Jpn. J. Antibiotic."},{"key":"e_1_3_2_3_28_1","unstructured":"National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5. 5th ed. National Committee for Clinical Laboratory Standards Wayne PA USA (2000)."},{"key":"e_1_3_2_3_29_1","unstructured":"National Committee for Clinical Laboratory Standards: MIC testing supplemental tables. M100-S10 (M7). National Committee for Clinical Laboratory Standards Wayne PA USA (2000)."},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.12.2496"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3616-3622.2001"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-002-0709-1"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2005.17.2.138"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.07.015"},{"key":"e_1_3_2_3_35_1","first-page":"S671","article-title":"Antibiotic susceptibility of Pseudomonas aeruginosa biofilm to ulifloxacin and other fluoroquinolones.","volume":"14","author":"Ceccarini P","year":"2008","unstructured":"Ceccarini P , Capezzone de JoannonA, RossiV: Antibiotic susceptibility of Pseudomonas aeruginosa biofilm to ulifloxacin and other fluoroquinolones.Clin. Microbiol. Infect.14(Suppl. 7) , S671 (2008).","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_2_3_36_1","first-page":"169","article-title":"Activity of ulifloxacin against clinical hospital isolates.","volume":"15","author":"Gemignani G","year":"2007","unstructured":"Gemignani G , TasciniC, LeonildiA, PiaggesiA, MenichettiF: Activity of ulifloxacin against clinical hospital isolates.Infez. Med.15 , 169\u2013173 (2007).","journal-title":"Infez. Med."},{"key":"e_1_3_2_3_37_1","volume-title":"The 47th Interscience Conference on Antimicrobial Agents and Chemotherapy.","author":"Fritsche TR","unstructured":"Fritsche TR , BiedenbachDJ, JonesRN: In vitro activity of ulifloxacin (active metabolite of prulifloxacin) tested against a worldwide collection of pathogen producing traveler\u2018s diarrhea. Proceedings of: The 47th Interscience Conference on Antimicrobial Agents and Chemotherapy.Chicago, IL, USA, 17\u201320 September 2007."},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.2.433-438.2001"},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.01.009"},{"key":"e_1_3_2_3_40_1","first-page":"56","article-title":"In vitro and in vivo antibacterial activity of NM441.","volume":"44","author":"Nishino T","year":"1996","unstructured":"Nishino T , TomiiY, ShibataKet al.: In vitro and in vivo antibacterial activity of NM441.Jpn. J. Chemother.44(Suppl. 1) , 56\u201369 (1996).","journal-title":"Jpn. J. Chemother."},{"key":"e_1_3_2_3_41_1","first-page":"1169","article-title":"Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.","volume":"46","author":"Tomii Y","year":"1996","unstructured":"Tomii Y , OzakiM, MatsudaMet al.: Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.Arzneimittelforschung46 , 1169\u20131173 (1996).","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1159\/000063623"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.4081\/uij.2003.69"},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.1159\/000084432"},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2007.19.3.304"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2003.07.006"},{"key":"e_1_3_2_3_47_1","first-page":"139","article-title":"The diabetic infected foot. Outpatients management and experience with prulifloxacin.","volume":"7","author":"Cavani E","year":"2007","unstructured":"Cavani E , PauraC: The diabetic infected foot. Outpatients management and experience with prulifloxacin.Trends Med.7 , 139\u2013147 (2007).","journal-title":"Trends Med."},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1086\/428055"},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80053-3"},{"key":"e_1_3_2_3_50_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K347"},{"key":"e_1_3_2_3_51_1","first-page":"1862","article-title":"Novel side effects of moxifloxacin: making a balanced decision again.","volume":"152","author":"Prins JM","year":"2008","unstructured":"Prins JM , KoopmansRP: Novel side effects of moxifloxacin: making a balanced decision again.Ned. Tijdschr. Geneeskd.152 , 1862\u20131864 (2008).","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"e_1_3_2_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(03)02180-0"},{"key":"e_1_3_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.2131\/jts.29.63"},{"key":"e_1_3_2_3_54_1","first-page":"102","article-title":"Convulsant effects of NM441, a prodrug type antibacterial agent of the quinolone class.","volume":"44","author":"Ukai Y","year":"1996","unstructured":"Ukai Y , YamazakiA, KurosakaC, IshimaT, YoshikuniY, KimuraK: Convulsant effects of NM441, a prodrug type antibacterial agent of the quinolone class.Jpn. J. Chemother.44(Suppl. 1) , 102\u2013112 (1996).","journal-title":"Jpn. J. Chemother."},{"key":"e_1_3_2_3_55_1","first-page":"113","article-title":"General pharmacological studies of NM441. (1) Effects on central and peripheral nervous systems, gastrointestinal tract and smooth muscle.","volume":"44","author":"Kura K","year":"1996","unstructured":"Kura K , FukuiT, OkamotoMet al.: General pharmacological studies of NM441. (1) Effects on central and peripheral nervous systems, gastrointestinal tract and smooth muscle.Jpn. J. Chemother.44(Suppl. 1) , 113\u2013128 (1996).","journal-title":"Jpn. J. Chemother."},{"key":"e_1_3_2_3_56_1","first-page":"129","article-title":"General pharmacological studies of NM441. (2) Effects on respiratory and cardiovascular systems, renal function and others.","volume":"44","author":"Kura K","year":"1996","unstructured":"Kura K , OchiS, TanakaMet al.: General pharmacological studies of NM441. (2) Effects on respiratory and cardiovascular systems, renal function and others.Jpn. J. Chemother.44(Suppl. 1) , 129\u2013146 (1996).","journal-title":"Jpn. J. Chemother."},{"key":"e_1_3_2_3_57_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200626010-00007"},{"key":"e_1_3_2_3_58_1","unstructured":"Prulifloxacin approved in Japan. Scrip 2790 22 (2002)."},{"key":"e_1_3_2_4_2_1","unstructured":"Kise M Kitano M Ozaki M et al.: Quinolinecarboxylic acid derivatives. Nippon Shinyaku Co. Ltd Kyoto Japan (1989). Patent AU 8824673 EP 0315828B1 JP 1989294680. www.freepatentsonline.com\/EP0315828B1.html (Accessed 20November2008)"},{"key":"e_1_3_2_4_3_1","unstructured":"European Medicines Agency. www.emea.europa.eu\/pdfs\/human\/press\/pr\/16089505en.pdf (Accessed 20November2008)"},{"key":"e_1_3_2_4_4_1","unstructured":"Optimer Pharmaceuticals Inc. www.optimerpharma.com (Accessed 20November2008)"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/17460913.4.1.13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:40:55Z","timestamp":1719124855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/17460913.4.1.13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.2217\/17460913.4.1.13"],"URL":"https:\/\/doi.org\/10.2217\/17460913.4.1.13","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}